Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShares IssuedShort-Term Debt issuances
Growth Metrics
Income Statement
Others
Ratios

Regen BioPharma (RGBP) Net Cash Flow (2016 - 2025)

Regen BioPharma (RGBP) has disclosed Net Cash Flow for 13 consecutive years, with -$64977.0 as the latest value for Q4 2025.

  • On a quarterly basis, Net Cash Flow fell 11102.93% to -$64977.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $4442.0, a 103.57% increase, with the full-year FY2025 number at $68839.0, up 157.21% from a year prior.
  • Net Cash Flow was -$64977.0 for Q4 2025 at Regen BioPharma, down from $67794.0 in the prior quarter.
  • In the past five years, Net Cash Flow ranged from a high of $538983.0 in Q3 2021 to a low of -$373670.0 in Q4 2021.
  • A 5-year average of -$1074.8 and a median of -$10463.0 in 2022 define the central range for Net Cash Flow.
  • Peak YoY movement for Net Cash Flow: soared 241.94% in 2023, then tumbled 11102.93% in 2025.
  • Regen BioPharma's Net Cash Flow stood at -$373670.0 in 2021, then skyrocketed by 97.2% to -$10463.0 in 2022, then surged by 133.08% to $3461.0 in 2023, then tumbled by 116.76% to -$580.0 in 2024, then crashed by 11102.93% to -$64977.0 in 2025.
  • Per Business Quant, the three most recent readings for RGBP's Net Cash Flow are -$64977.0 (Q4 2025), $67794.0 (Q3 2025), and -$1.0 (Q2 2025).